Amgen Reports Kras Safety Update
FDA has approved revisions to the US prescribing information for Amgen’s epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix (panitumumab). The decision follows the FDA’s December
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).